Tildren

Tildren is a treatment for lameness associated with bone and cartilage changes in bone splints (hamstring tumor) and the quirt syndrome (or Podotrochlear syndrome, necrotic disease, digital heel pain, or "headache" pain), for recent development in horses. Dose: Dilute the vial in a sterile manner using the lyophilized powder with the diluent that comes with the product. Administer 0.1 mg of Tiludronic acid per kilogram of body weight daily for 10 days, intravenously with the help of a syringe and needle or catheter (preferably in the jugular vein), slowly over more than 30 minutes, i.e., 1 ml of the reconstituted solution per 50 kg live weight daily. Given intravenously. Precautions: It is recommended to monitor the horse during the first three hours after injection due to the possibility of adverse reactions. Use during pregnancy and lactation: The safety of this drug has not been studied in pregnant or lactating mares. This drug is not recommended for use in mares during pregnancy or lactation.